As part of the agreement, the two companies will jointly market their services to biomedical companies, insurers and government agencies worldwide. World Health Information Science Consultants (WHISCON) will draw upon PPD’s experience in large drug studies, both pre- and post-approval.
In turn, PPD will leverage WHISCON’s client relationships and global safety expertise in conducting epidemiology, risk management, pharmacovigilance, and observational and database studies.
Fred Eshelman, CEO of PPD, said: “Epidemiology is playing a larger, more important role in understanding and evaluating risks related to drug safety. Our agreement with WHISCON will enhance our ability to help clients identify and manage the benefits and risks of their marketed products.”